Atrium Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
RNA$8.23-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(in thousands except share and per share information)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Collaboration revenue | $19,635 | $1,573 |
| Operating expenses: | ||
| Research and development | 16,657 | 6,937 |
| General and administrative | 20,258 | 2,088 |
| Total operating expenses | 36,915 | 9,025 |
| Loss from operations | (17,280) | (7,452) |
| Other income, net | 647 | 3 |
| Net loss and comprehensive loss | $(16,633) | $(7,449) |
| Basic and diluted net loss per common share | $(0.97) | $(0.44) |
| Weighted average common shares outstanding used in the calculation of basic and diluted net loss per common share | 17,105,643 | 17,105,643 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.